Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis
Nature Medicine2017Vol. 23(5), pp. 590–600
Citations Over TimeTop 1% of 2017 papers
Luigina Romani, Vasileios Oikonomou, Silvia Moretti, Rossana G. Iannitti, Maria Cristina D’Adamo, Valeria Rachela Villella, Marilena Pariano, Luigi Sforna, Monica Borghi, Marina Maria Bellet, Francesca Fallarino, Maria Teresa Pallotta, Giuseppe Servillo, Eleonora Ferrari, Paolo Puccetti, Guido Kroemer, Mauro Pessia, Luigi Maiuri, Allan L. Goldstein, Enrico Garaci
Related Papers
- → Sulfamoyl-4-oxoquinoline-3-carboxamides: Novel potentiators of defective ΔF508-cystic fibrosis transmembrane conductance regulator chloride channel gating(2005)33 cited
- → Model of the cAMP activation of chloride transport by CFTR channel and the mechanism of potentiators(2009)21 cited
- → 59 A Cochrane review of CFTR potentiators in cystic fibrosis(2013)
- → P041 Effect of the triple combination of CFTR correctors and potentiator on lung function, BMI and the Brasfield score in adolescents with cystic fibrosis(2021)
- → 609: Elexacaftor as a CFTR potentiator: Synergism with ivacaftor and implications for new combination drug therapies for cystic fibrosis(2021)